Shaya Mahati, Xiaoyun Peng, Zhao Yin, Guangchao Li, Wenbin Li
{"title":"Angiopep2 (Ang-2) peptide linked DNA walker assay for sensitive and accurate detection of glioma cell.","authors":"Shaya Mahati, Xiaoyun Peng, Zhao Yin, Guangchao Li, Wenbin Li","doi":"10.1016/j.talanta.2025.128903","DOIUrl":null,"url":null,"abstract":"<p><p>Liquid biopsy has emerged as a promising alternative for glioma detection; however, the blood-brain barrier restricts the abundance of circulating tumor cells (CTCs) in peripheral blood, posing a significant challenge for sensitive CTCs-based diagnostics of glioma. To address this limitation, we present an Angiopep2 (Ang-2) peptide linked DNA walker assay for colorimetric glioma cell detection with high sensitivity and specificity. This system integrates Ang-2 and a cholesterol labeled tracker (cholesterol-tracker) as dual-targeting ligands, coupled with a DNA walker-mediated signal amplification strategy for enhanced sensitivity and specificity. Compared to conventional immunoassays relying on monoclonal antibodies, our platform demonstrates superior performance due to its preferential binding to intact glioma cells and the signal amplification induced by the λ-exonuclease-driven DNA walking mechanism. The biosensor achieved an exceptionally low detection limit of 0.12 cells/mL and exhibited strong anti-interference capabilities across multiple cell lines. Furthermore, the biosensor maintained ≥96 % of initial signal retained after 21 days at 4 °C (96.5 % ± 0.35, n = 3), with only marginal signal attenuation observed. Clinical validation using constructed serum samples revealed excellent agreement in glioma concentration calculated by the proposed sensing platform and added glioma cell concentrations. Collectively, our findings demonstrate that this sensing platform represents a rapid, sensitive, specific, and portable technology for the detection of U251 glioblastoma cells, with potential applications in clinical diagnostics of glioma.</p>","PeriodicalId":435,"journal":{"name":"Talanta","volume":"298 Pt A","pages":"128903"},"PeriodicalIF":6.1000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Talanta","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1016/j.talanta.2025.128903","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Liquid biopsy has emerged as a promising alternative for glioma detection; however, the blood-brain barrier restricts the abundance of circulating tumor cells (CTCs) in peripheral blood, posing a significant challenge for sensitive CTCs-based diagnostics of glioma. To address this limitation, we present an Angiopep2 (Ang-2) peptide linked DNA walker assay for colorimetric glioma cell detection with high sensitivity and specificity. This system integrates Ang-2 and a cholesterol labeled tracker (cholesterol-tracker) as dual-targeting ligands, coupled with a DNA walker-mediated signal amplification strategy for enhanced sensitivity and specificity. Compared to conventional immunoassays relying on monoclonal antibodies, our platform demonstrates superior performance due to its preferential binding to intact glioma cells and the signal amplification induced by the λ-exonuclease-driven DNA walking mechanism. The biosensor achieved an exceptionally low detection limit of 0.12 cells/mL and exhibited strong anti-interference capabilities across multiple cell lines. Furthermore, the biosensor maintained ≥96 % of initial signal retained after 21 days at 4 °C (96.5 % ± 0.35, n = 3), with only marginal signal attenuation observed. Clinical validation using constructed serum samples revealed excellent agreement in glioma concentration calculated by the proposed sensing platform and added glioma cell concentrations. Collectively, our findings demonstrate that this sensing platform represents a rapid, sensitive, specific, and portable technology for the detection of U251 glioblastoma cells, with potential applications in clinical diagnostics of glioma.
期刊介绍：
Talanta provides a forum for the publication of original research papers, short communications, and critical reviews in all branches of pure and applied analytical chemistry. Papers are evaluated based on established guidelines, including the fundamental nature of the study, scientific novelty, substantial improvement or advantage over existing technology or methods, and demonstrated analytical applicability. Original research papers on fundamental studies, and on novel sensor and instrumentation developments, are encouraged. Novel or improved applications in areas such as clinical and biological chemistry, environmental analysis, geochemistry, materials science and engineering, and analytical platforms for omics development are welcome.
Analytical performance of methods should be determined, including interference and matrix effects, and methods should be validated by comparison with a standard method, or analysis of a certified reference material. Simple spiking recoveries may not be sufficient. The developed method should especially comprise information on selectivity, sensitivity, detection limits, accuracy, and reliability. However, applying official validation or robustness studies to a routine method or technique does not necessarily constitute novelty. Proper statistical treatment of the data should be provided. Relevant literature should be cited, including related publications by the authors, and authors should discuss how their proposed methodology compares with previously reported methods.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
